Zacks: Analysts Anticipate Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Will Post Earnings of -$1.00 Per Share

Equities research analysts expect that Freeline Therapeutics Holdings plc (NASDAQ:FRLN) will post earnings per share (EPS) of ($1.00) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Freeline Therapeutics’ earnings, with estimates ranging from ($1.12) to ($0.88). The business is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Freeline Therapeutics will report full year earnings of ($3.73) per share for the current year, with EPS estimates ranging from ($3.88) to ($3.39). For the next financial year, analysts expect that the firm will report earnings of ($3.15) per share, with EPS estimates ranging from ($4.06) to ($1.89). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Freeline Therapeutics.

Freeline Therapeutics (NASDAQ:FRLN) last announced its quarterly earnings results on Monday, August 16th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.19).

A number of equities analysts have weighed in on FRLN shares. Zacks Investment Research raised shares of Freeline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 20th. JPMorgan Chase & Co. cut shares of Freeline Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $27.00 to $8.00 in a research report on Tuesday, August 17th. HC Wainwright cut their target price on shares of Freeline Therapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, August 18th. Finally, Mizuho lowered shares of Freeline Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 16th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $19.29.

A hedge fund recently raised its stake in Freeline Therapeutics stock. Morgan Stanley increased its holdings in shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) by 50.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,637 shares of the company’s stock after acquiring an additional 11,314 shares during the quarter. Morgan Stanley owned approximately 0.09% of Freeline Therapeutics worth $274,000 at the end of the most recent quarter. 31.54% of the stock is owned by institutional investors and hedge funds.

NASDAQ:FRLN traded up $0.05 on Monday, reaching $3.35. The stock had a trading volume of 500 shares, compared to its average volume of 113,436. The company has a 50-day moving average of $3.66 and a 200 day moving average of $7.42. The stock has a market cap of $119.93 million, a P/E ratio of -0.49 and a beta of -0.95. Freeline Therapeutics has a 12-month low of $2.92 and a 12-month high of $18.88.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B.

Featured Article: What’s a Black Swan?

Get a free copy of the Zacks research report on Freeline Therapeutics (FRLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.